Published in Cancer on March 01, 2008
Standards of care for treatment of recurrent glioblastoma--are we there yet? Neuro Oncol (2012) 2.31
New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol (2008) 1.58
The future of high-grade glioma: Where we are and where are we going. Surg Neurol Int (2015) 1.50
Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol (2008) 1.41
Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol (2013) 1.25
Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol (2010) 1.10
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol (2010) 1.06
Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol (2011) 1.06
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol (2013) 0.96
Nonsurgical treatment of recurrent glioblastoma. Curr Oncol (2015) 0.90
Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. Neuro Oncol (2015) 0.90
Role of MGMT as biomarker in colorectal cancer. World J Clin Cases (2014) 0.86
Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells. Oncol Lett (2010) 0.85
MicroRNA-542-3p Suppresses Tumor Cell Invasion via Targeting AKT Pathway in Human Astrocytoma. J Biol Chem (2015) 0.85
Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience. Radiat Oncol (2013) 0.83
Ursolic acid attenuates temozolomide resistance in glioblastoma cells by downregulating O(6)-methylguanine-DNA methyltransferase (MGMT) expression. Am J Transl Res (2016) 0.79
Recurrent malignant gliomas. Semin Radiat Oncol (2014) 0.79
Direct inhibition of retinoblastoma phosphorylation by nimbolide causes cell-cycle arrest and suppresses glioblastoma growth. Clin Cancer Res (2013) 0.78
Design, synthesis, and evaluation of curcumin-derived arylheptanoids for glioblastoma and neuroblastoma cytotoxicity. Bioorg Med Chem Lett (2013) 0.77
Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics. Oncotarget (2015) 0.75
Achievement of three year remission with bevacizumab and irinotecan in recurrent glioblastoma multiforme: a case report. Clin Med Insights Oncol (2011) 0.75
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer (2010) 2.74
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res (2010) 2.56
Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol (2003) 2.30
Profile of daily life in children with brain tumors: an assessment of health-related quality of life. J Clin Oncol (2005) 2.26
Pancreatic cancer and thromboembolic disease. Lancet Oncol (2004) 2.10
Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol (2007) 2.09
Phase I/II study of resection and intraoperative cesium-131 radioisotope brachytherapy in patients with newly diagnosed brain metastases. J Neurosurg (2014) 2.03
Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res (2010) 1.92
Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci U S A (2011) 1.86
The future of neurosurgery: a white paper on the recruitment and retention of women in neurosurgery. J Neurosurg (2008) 1.73
Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann Neurol (2007) 1.64
Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. J Neurosurg (2009) 1.64
A syndrome of irreversible leukoencephalopathy following pediatric allogeneic bone marrow transplantation. Pediatr Blood Cancer (2007) 1.51
Language matters: "sometimes we withdraw treatment but we never withdraw care". J Palliat Med (2007) 1.45
Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study. Pediatr Blood Cancer (2008) 1.37
Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. J Clin Oncol (2009) 1.24
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer (2012) 1.21
Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery (2011) 1.14
Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol (2013) 1.12
Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors. Clin Cancer Res (2006) 1.12
A phase II study of metronomic oral topotecan for recurrent childhood brain tumors. Pediatr Blood Cancer (2011) 1.10
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol (2008) 1.06
Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene (2003) 1.06
Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neurooncol (2008) 1.05
Gender affects survival for medulloblastoma only in older children and adults: a study from the Surveillance Epidemiology and End Results Registry. Pediatr Blood Cancer (2009) 1.04
Selective depletion of mutant p53 by cancer chemopreventive isothiocyanates and their structure-activity relationships. J Med Chem (2011) 1.03
Cortical ependymoma. A case report and review. Pediatr Neurosurg (2003) 1.00
Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143. Cancer Res (2003) 1.00
Verbal memory impairments in children after cerebellar tumor resection. Behav Neurol (2008) 0.99
Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor. Pituitary (2011) 0.98
Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs (2005) 0.98
Radiation therapy for intracranial germ cell tumors. Int J Radiat Oncol Biol Phys (2003) 0.98
Advances in the Genetic Screening, Work-up, and Treatment of Pancreatic Cancer. Curr Treat Options Gastroenterol (2004) 0.96
Subventricular spread of diffuse intrinsic pontine glioma. Acta Neuropathol (2014) 0.95
Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. J Natl Cancer Inst (2013) 0.93
A novel stereo-selective sulfonylurea, 1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one, has antitumor efficacy in in vitro and in vivo tumor models. Biochem Pharmacol (2002) 0.92
Diffusion-weighted MRI derived apparent diffusion coefficient identifies prognostically distinct subgroups of pediatric diffuse intrinsic pontine glioma. J Neurooncol (2014) 0.91
Head and neck squamous cell carcinoma in FAMMM syndrome. Head Neck (2009) 0.91
Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas. Proc Natl Acad Sci U S A (2007) 0.91
Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival. J Gastrointest Surg (2007) 0.91
Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro Oncol (2012) 0.90
The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. J Neurosurg (2006) 0.90
NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells. Biochemistry (2004) 0.90
Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. Urol Oncol (2005) 0.89
Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway. Mol Cancer Ther (2005) 0.89
Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas. Pancreas (2008) 0.89
Transient cerebral hypoperfusion enhances intraarterial carmustine deposition into brain tissue. J Neurooncol (2007) 0.89
The intensity and frequency of moral distress among different healthcare disciplines. J Clin Ethics (2013) 0.89
Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. J Neurooncol (2014) 0.88
Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol (2003) 0.88
Cost savings from palliative care teams and guidance for a financially viable palliative care program. Health Serv Res (2014) 0.88
New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting. Clin Cancer Res (2005) 0.87
Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Neuro Oncol (2008) 0.86
Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro Oncol (2008) 0.86
Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-terminal peptide. Mol Cancer Ther (2006) 0.86
Loss of SMARCB1/INI1 expression in poorly differentiated chordomas. Acta Neuropathol (2010) 0.86
A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood. Neuro Oncol (2013) 0.85
Correlation between hydrophobic properties and efficiency of carrier-mediated membrane transduction and apoptosis of a p53 C-terminal peptide. Biochem Biophys Res Commun (2002) 0.85
Activation of targeted necrosis by a p53 peptide: a novel death pathway that circumvents apoptotic resistance. J Biol Chem (2007) 0.85
PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer (2006) 0.85
Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study. Pediatr Blood Cancer (2005) 0.85
Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients. J Neurooncol (2006) 0.84
High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery (2014) 0.84
The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells. Clin Cancer Res (2002) 0.84
Intra-arterial mitoxantrone delivery in rabbits: an optical pharmacokinetic study. Neurosurgery (2011) 0.83
Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania. Cancer Invest (2005) 0.83
Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy. J Neurooncol (2006) 0.83
In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines. Radiat Oncol (2013) 0.83
Selective induction of apoptosis through the FADD/caspase-8 pathway by a p53 c-terminal peptide in human pre-malignant and malignant cells. Int J Cancer (2005) 0.83
Birth anomalies and obstetric history as risks for childhood tumors of the central nervous system. Pediatrics (2011) 0.83
Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies. Invest New Drugs (2009) 0.82
Hedgehogs, flies, Wnts and MYCs: the time has come for many things in medulloblastoma. J Clin Oncol (2011) 0.81
Congenital glioblastoma multiforme: case report and review of the literature. Pediatr Neurosurg (2008) 0.81
Use of human neural tissue for the generation of progenitors. Neurosurgery (2008) 0.81
The role of alpha-helical structure in p53 peptides as a determinant for their mechanism of cell death: necrosis versus apoptosis. Adv Drug Deliv Rev (2005) 0.80
Treatment preferences of seriously ill patients. N Engl J Med (2002) 0.80
Feasibility of using hyperosmolar mannitol as a liquid tumor embolization agent. AJNR Am J Neuroradiol (2005) 0.80
The use of fluorescent probes in the study of reactive oxygen species in pancreatic cancer cells. Methods Mol Biol (2013) 0.80
Relapse patterns in pediatric embryonal central nervous system tumors. J Neurooncol (2013) 0.80
Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium. Clin Cancer Res (2002) 0.79
Liposomal cytarabine for central nervous system embryonal tumors in children and young adults. J Neurooncol (2010) 0.79
Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDAC. Mol Cancer Ther (2013) 0.79
The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX. Surg Oncol Clin N Am (2004) 0.79
Are neonatal stroke and hypoxic-ischemic encephalopathy related? J Pediatr (2016) 0.79
The feasibility of real-time in vivo optical detection of blood-brain barrier disruption with indocyanine green. J Neurooncol (2011) 0.79
Paclitaxel delivery to brain tumors from hydrogels: a computational study. Biotechnol Prog (2011) 0.78
Corticomedullary strain ratio: a quantitative marker for assessment of renal allograft cortical fibrosis. J Ultrasound Med (2013) 0.78
Effect of levetiracetam on testosterone levels in male patients. Epilepsia (2010) 0.78
Stereotactic radiosurgery plays a critical role in enhancing long-term survival in a patient with pancreatic cancer metastatic to the brain. Anticancer Res (2013) 0.78
Trends in the diagnosis and treatment of pediatric primary spinal cord tumors. J Neurosurg Pediatr (2012) 0.77
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies. Cancer (2003) 0.77
It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol (2011) 0.77
Fly through ultrasound imaging in assessment of carotid atherosclerosis: a pictorial essay. Clin Imaging (2013) 0.77
Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature. Oncology (2012) 0.77
Surveillance imaging in children with malignant CNS tumors: low yield of spine MRI. J Neurooncol (2014) 0.77
Significant reduction of laparotomy-associated lung metastases and subcutaneous tumors after perioperative immunomodulation with flt3 ligand in mice. Surg Innov (2005) 0.77